Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer [1]

Journal of Internal Medicine

Volumn 260, Issue 6, 2006, Pages 592-593

  Mascitelli, L ^a,c   Pezzetta, F ^b  

^a Sanitary Service   (Italy)

^b Ospedale San Vito   (Italy)

^c Italian Army ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

ATHEROSCLEROTIC PLAQUE; BREAST CARCINOMA; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; ESOPHAGUS CARCINOMA; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LETTER; MELANOMA; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; HEPTANOIC ACIDS; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; PYRROLES; T-LYMPHOCYTES;

EID: 33751093028     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01717.x     Document Type: Letter

References (13)

1. Solem J, Levin M, Karlsson T, Grip L, Albertsson P, Wiklund O. Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment. J Intern Med 2006; 259: 267-75.
2. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13.
3. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-6.
4. Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74: 492-501.
5. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30: 1797-803.
6. Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol 1997; 24 (Suppl 4): S2-S7.
7. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
8. Nakano O, Sato M, Naito Y et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61: 5132-6.
9. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
10. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
11. Shepherd S, Blauw GJ, Murphy MB et al. on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-30.
12. Pedersen TR, Berg K, Cook TJ et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-92.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomized placebo controlled trial. Lancet 2002; 360: 7-22.